BioAlliance Pharma Announces the Execution of its Licensing Agreement With Vestiq Pharmaceuticals for Oravig® in the U.S.

Published: Sep 24, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO) (Paris:BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the execution of the licensing agreement with Vestiq Pharmaceuticals to commercialize Oravig® in the United States (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis in adults.

Back to news